首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1518527

基因治療臨床試驗服務市場 - 按服務（臨床試驗設計和規劃、供應和物流、監管、數據管理和生物統計）、治療領域（腫瘤、肌肉骨骼、CVD）、最終用戶 - 全球預測（2024 - 2032）

Gene Therapy Clinical Trial Services Market - By Services (Clinical Trial Design & Planning, Supply & Logistics, Regulatory, Data Management & Biostatistics), Therapeutic Areas (Oncology, Musculoskeletal, CVD), End-user - Global Forecast (2024 - 2032)

出版日期: 2024年04月30日 | 出版商:

Global Market Insights Inc. | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在積極的監管措施和不斷成長的研發投資的推動下，2024-2032年全球基因療法臨床試驗服務市場的複合年成長率將達到9.2%。

慢性病發病率的不斷上升是市場成長的主要動力。據世界衛生組織稱，非傳染性疾病 (NCD) 每年奪去 4,100 萬人的生命，佔所有死亡人數的 74%。癌症、心血管疾病和神經退化性疾病等疾病給醫療保健系統帶來了沉重負擔。傳統的治療程序只提供表面護理或控制症狀，而沒有解決這些疾病的根本遺傳原因。基因療法提供了一種從根源解決非傳染性疾病的有吸引力的方法，提供治癒或緩解疾病的治療方法。隨著全球慢性健康疾病的發病率持續激增，對創新治療解決方案的需求不斷增加，從而推動市場成長。

全球基因療法臨床試驗服務業根據服務、治療領域、最終用戶和地區進行分類。

到 2032 年，供應鏈和物流服務領域的佔有率將快速成長，因為基於基因的治療（包括個人化療法和病毒載體）的複雜性使得必須對供應鏈運作進行細緻的規劃和執行。從採購原料和管理冷鏈物流到確保研究產品的按時交付，這些服務對於進行基因療法臨床試驗至關重要。服務提供者根據每次試驗的具體需求提供全面的供應鏈解決方案，從而實現高效、合規的試驗。

肌肉骨骼疾病領域的基因治療臨床試驗服務市佔率將在2024 年至2032 年期間大幅成長，因為這些疾病，包括退化性關節疾病、肌肉營養不良和骨骼疾病，給全球醫療保健系統帶來沉重負擔。基因療法在認知與這些疾病相關的潛在遺傳缺陷方面具有很大的潛力，為疾病修飾和功能改善提供了可能性。因此，專注於基於基因的肌肉骨骼疾病干預措施的臨床試驗正在獲得動力，從而引發了根據這些試驗的獨特要求量身定做的專業服務的需求。

由於強大的醫療基礎設施、嚴格的監管框架以及不斷成長的研發投資，到 2032 年，歐洲基因療法臨床試驗服務產業規模將快速成長。英國、德國、法國和瑞士等國家在基因治療研究和創新方面處於領先地位，擁有充滿活力的臨床試驗服務生態系統。此外，學術機構、生物製藥公司和合約研究組織（CRO）之間的合作正在推動該地區基因治療臨床試驗的進步。憑藉有利的監管環境和大量的基因治療候選藥物，歐洲市場必將大幅成長。

產業生態系統分析
產業影響力
- 成長動力
  - 臨床試驗的全球化
  - 遺傳疾病和慢性病盛行率不斷上升
  - 基因治療技術不斷進步
  - 擴大在腫瘤學和罕見疾病的應用
- 產業陷阱與挑戰
  - 嚴格的監管挑戰
成長潛力分析
監管環境
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按服務分類，2021 - 2032 年

主要趨勢
臨床試驗設計與規劃
供應及物流服務
監管服務
數據管理和生物統計學
現場管理和監控
其他服務

第 6 章：市場估計與預測：按服務分類，2021 - 2032 年

主要趨勢
腫瘤學
血液學
內分泌/代謝紊亂
肌肉骨骼
心血管疾病（CVD）
神經系統疾病
傳染病
眼科
免疫學
其他治療領域

第 7 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

主要趨勢
製藥和生物技術公司
合約研究組織 (CRO)
學術及研究機構
其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Almac Group
Catalent Biologics
Charles River Laboratories International, Inc.
ICON plc
IQVIA Biotech
Labcorp Drug Development
Medpace Holdings, Inc.
Novotech
Parexel International (MA) Corporation
Precision Medicine Group LLC
Sharp Services, LLC
Thermo Fisher Scientific Inc.
Worldwide Clinical Trials

簡介目錄

Product Code: 9312

Global Gene Therapy Clinical Trial Services Market will record 9.2% CAGR during 2024-2032, driven by positive regulatory initiatives and growing investments in R&D.

The growing incidence of chronic ailments acts as a major growth driver in the market. According to WHO, noncommunicable diseases (NCDs) kill 41 million individuals annually, contributing to 74% of all deaths. Diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions, have placed substantial burden on healthcare systems. Traditional treatment procedures offer superficial care or manage symptoms without addressing the underlying genetic causes of these diseases. Gene therapy provides an appealing approach to tackle NCDs at their roots, offering curative or disease-modifying treatments. As the incidence of chronic health diseases continues to surge globally, there is rising demand for innovative therapeutic solutions, thereby propelling market growth.

Global gene therapy clinical trial services industry is classified based on services, therapeutic areas, end-user, and region.

Supply chain & logistics service segment share will grow rapidly through 2032, as the complex nature of gene-based treatments, including personalized therapies and viral vectors, makes meticulous planning and execution of supply chain operations mandatory. From sourcing raw materials and managing cold chain logistics to ensuring on-time delivery of investigational products, these services are essential to conduct of gene therapy clinical trials. The service providers offer comprehensive supply chain solutions tailored to the specific demand of each trial, thereby allowing efficient and compliant trials.

Gene therapy clinical trial services market share from musculoskeletal disorders segment will witness a decent surge during 2024-2032, as these conditions, including degenerative joint diseases, muscular dystrophies, and bone disorders, impose a heavy burden on healthcare systems globally. Gene therapy holds a lot of potential in acknowledging the underlying genetic defects associated with these disorders, providing the possibility of disease modification and functional improvement. Clinical trials, that are focused on gene-based interventions for musculoskeletal disorders are thus gaining momentum, inducing demand for specialized services tailored to the unique requirements of these trials.

Europe gene therapy clinical trial services industry size will grow rapidly through 2032, owing to the robust healthcare infrastructure, stringent regulatory framework, and growing investments in R&D . Nations such as the United Kingdom, Germany, France, and Switzerland are leading gene therapy research and innovation, harboring a vibrant ecosystem for clinical trial services. Moreover, collaborations between academic institutions, biopharmaceutical companies, and contract research organizations (CROs) are fueling the advancement of gene therapy clinical trials in the region. With a favorable regulatory environment and a large number of gene therapy candidates, Europe market is set to witness substantial growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Globalization of clinical trials
  - 3.2.1.2 Increasing prevalence of genetic and chronic diseases
  - 3.2.1.3 Growing advancements in gene therapy technologies
  - 3.2.1.4 Expanded applications in oncology and rare diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory challenges
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Services, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Clinical trial design & planning
5.3 Supply & logistics services
5.4 Regulatory services
5.5 Data management & biostatistics
5.6 Site management & monitoring
5.7 Other services

Chapter 6 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oncology
6.3 Hematology
6.4 Endocrine/ metabolic disorders
6.5 Musculoskeletal
6.6 Cardiovascular diseases (CVD)
6.7 Neurology disorders
6.8 Infectious disease
6.9 Ophthalmology
6.10 Immunology
6.11 Other therapeutic areas

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pharmaceutical & biotechnology companies
7.3 Contract research organizations (CROs)
7.4 Academic and research institutes
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa